Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.80 and traded as low as $0.68. Karyopharm Therapeutics shares last traded at $0.70, with a volume of 433,181 shares.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KPTI. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, January 15th. Finally, Piper Sandler raised their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Price Performance

The firm has a market cap of $88.32 million, a price-to-earnings ratio of -0.61 and a beta of 0.07. The stock has a 50-day moving average of $0.73 and a 200-day moving average of $0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. On average, equities analysts expect that Karyopharm Therapeutics Inc. will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP increased its holdings in Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after purchasing an additional 792,283 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after buying an additional 43,856 shares in the last quarter. AQR Capital Management LLC boosted its stake in Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after acquiring an additional 622,194 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $494,000. Finally, FMR LLC increased its holdings in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares in the last quarter. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).